Clinical Trials Browser

Phase 3 × Darbepoetin alfa × Tumor-Agnostic × Clear all

NCT00135317 2013-05-23

AIM 3: Anemia and Iron Management With Every 3 Week Dosing in Anemic Subjects With Nonmyeloid Malignancies

Phase 3 Completed

Neoplasms